Electrolyte Imbalance · Calcium SupplementRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Calcium Gluconate by Caplin

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 12:33:12 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Caplin's ANDA for Calcium Gluconate is a significant regulatory milestone that could enhance Caplin's competitive position in the calcium supplement market. Portfolio teams should closely monitor this development to assess its implications for market dynamics and competitive strategies. Regulatory context from FDA (FDA AP — CALCIUM GLUCONATE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for calcium supplements and consider strategic positioning. The strongest clinical anchor is MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (ClinicalTrials.gov), moderate corpus alignment. In Electrolyte Imbalance · Calcium Supplement, 8 regulatory and 1 competitive items passed relevance filtering for Caplin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may position Caplin to compete in the calcium supplement market, potentially impacting existing players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CALCIUM GLUCONATE (ORIG) (FDA). Entity match (caplin); Regulatory pathway relevance (nda). The acceptance of the ANDA indicates a step towards potential market entry, but final approval and compliance will still need to be monitored.

Key Risks

Elevated medium regulatory exposure for Caplin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If Caplin successfully enters the market, it could disrupt existing players and alter market share dynamics in the calcium supplement sector.
Upside for Caplin may improve if Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Caplin may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the competitive landscape for calcium supplements and consider strategic positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and market entry of Caplin's Calcium Gluconate.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CALCIUM GLUCONATE (ORIG)
FDAhigh relevance
Entity match (caplin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ATORVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CALCIUM ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Effects of carbohydrate-electrolyte solutions with and without L-menthol on hydration and performance recovery following simulated firefighting exercise.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Caplin

Commercial impact

medium

If Caplin successfully enters the market, it could disrupt existing players and alter market share dynamics in the calcium supplement sector.

Regulatory impact

medium

The acceptance of the ANDA indicates a step towards potential market entry, but final approval and compliance will still need to be monitored.

What to watch

Monitor the timeline for final approval and market entry of Caplin's Calcium Gluconate.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.